Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 single ascending dose study in healthy volunteers
NCT02792686Phase 1Completed
- Sponsor
- Abivax
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obefazimod in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Abivax. Primary endpoint: Adverse Events at 45 days. Started Mar 2014; status: completed.
02
Drugs
obefazimod
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02792686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792686.